Results 11 to 20 of about 8,510 (199)

The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients. [PDF]

Mol Oncol
Clinical outcomes in ROS1-fusion positive (ROS1+) non-small cell lung cancer (NSCLC) by fusion partner and resistance mechanisms are limited. This cohort study included 56 ROS1+ patients (FISH or NGS confirmed); fusion partners were identified in 27 ...
Zwierenga F, Dijkhuizen C, Korthuis P, Timens W, Groen H, Hiltermann J, van den Berg A, Drayer L, van der Wekken A.   +8 more
europepmc   +4 more sources

Clinical characteristics of the ALK fusion-positive bladder PMP and efficacy of lorlatinib: a two-case report and literature review. [PDF]

Oncologist
Pseudosarcomatous myofibroblastic proliferation (PMP) is a rare anaplastic lymphoma kinase (ALK), ALK fusion-associated tumor-like lesion that requires differentiation from inflammatory myofibroblastic tumor (IMT).
Sun M, Ju M, Zhang H, Huang N, Zhang S, Sun M.   +5 more
europepmc   +2 more sources

Managing lorlatinib-induced weight gain through a structured exercise intervention in an ALK+ NSCLC patient: a case report. [PDF]

Front Oncol
Background In non-small cell lung cancer (NSCLC), ALK tyrosine kinase inhibitors (TKIs) have been associated with significant weight gain, predominantly in fat tissues.
Ciurnelli C, Mariangela Scaglione I, Eccher S, Borsati A, Toniolo L, Adamoli G, Tregnago D, Longo L, Sposito M, Insolda J, Milella M, Schena F, Quist M, Belluomini L, Pilotto S, Avancini A.   +15 more
europepmc   +2 more sources

A pragmatic guide for management of adverse events associated with lorlatinib [PDF]

Lung Cancer
Anaplastic lymphoma kinase; Carcinoma; Tyrosine kinase inhibitorsLinfoma quinasa anaplásico; Carcinoma; Inhibidores de la tirosina quinasaLimfoma quinasa anaplàstic; Carcinoma; Inhibidors de la tirosina cinasaLorlatinib is a brain-penetrant, third ...
Bauer, Todd, FELIP, ENRIQUETA, Liu, Geoffrey, MAZIERES, JULIEN, Mok, Tony, Ou, Sai-Hong, Stratmann, Jan   +6 more
core   +2 more sources

An <i>in silico</i> evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer. [PDF]

Front Pharmacol
The anaplastic lymphoma kinase (alk) gene on chromosome 2 encodes a receptor tyrosine kinase protein essential for key signaling pathways regulating cell proliferation and differentiation.
Zapata Dongo RJ, Poterico JA, Fontana D, Mologni L, Alvarez-Chacon C, Rojas-Armas J, Calla J.   +6 more
europepmc   +2 more sources

First case report of lorlatinib in the treatment of ALK-fusion-positive lung adenocarcinoma with ovarian metastasis: Clinicopathological and molecular characterization. [PDF]

Medicine (Baltimore)
Background: Ovarian metastasis from anaplastic lymphoma kinase (ALK)-positive lung adenocarcinoma is exceedingly rare. Reporting such cases is vital for understanding its clinical management.
Xu T, Hua S, Wang J, Wu M, Qiu X, Hong J, Zhang Y, Shao K, Wang J.   +8 more
europepmc   +2 more sources

Long-Term Safety and Management of Adverse Events Associated With Lorlatinib in <i>ALK</i>-Positive Metastatic NSCLC: A Fictional Case Study. [PDF]

J Adv Pract Oncol
Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in about 3% to 7% of patients with non-small cell lung cancer (NSCLC) and are the key drivers of cancer cell proliferation in ALK-positive NSCLC. ALK tyrosine kinase inhibitors (TKIs)
Krueger EA, Castronovo E, Cho E, Alejandro L, Mcdonald S, Oshiro CB, Lewis W.   +6 more
europepmc   +2 more sources

Safety of Lorlatinib in Patients with Unresectable Advanced ALK-Positive Non-Small-Cell Lung Cancer Previously Treated with ALK Inhibitors: A Single-Arm, Open-Label, Phase IV Study in India

Indian Journal of Medical and Paediatric Oncology
Lorlatinib is approved in India for patients with previously treated anaplastic lymphoma kinase (ALK)–positive advanced or recurrent non-small-cell lung cancer (NSCLC).
Ullas Batra, Vineet G. Gupta, Nirmal Raut, Tushar Patil, Harsha Panchal, Nikhil Ghadyalpatil, Anand Pathak, Chirag Desai, Shailesh Bondarde, Minish Jain, Christian Russel Reyes, Shyam Parvatini, Seema Pai, Francesca Toffalorio, Holger Thurm, Bivas Biswas   +15 more
doaj   +2 more sources

Navigating treatment sequencing in ALK-positive non-small cell lung cancer: lorlatinib as a key to prolonged survival? [PDF]

Transl Lung Cancer Res
based on ALK and ROS1 status and previous treatments, assessing lorlatinib’s efficacy and safety. Lorlatinib demonstrated significant overall and intracranial efficacy in ALK + NSCLC, both in treatment-naïve patients and those who had received previous ...
Ulhøi MP, Meldgaard P.
europepmc   +2 more sources

Cabozantinib overcomes ROS1 L2086F NSCLC resistance to lorlatinib: A case report. [PDF]

Medicine (Baltimore)
Rationale: ROS1 rearrangement a distinct molecular subtype of non-small cell lung cancer that is amenable to targeted therapeutic interventions. Despite the availability of effective targeted therapies, the development of acquired resistance to later ...
Liu X, Chen Q, Shao L, Luo P, An JH.
europepmc   +2 more sources